A randomized controlled phase III study comparing hadrontherapy with carbon ions versus conventional radiotherapy – including photon and proton therapy – for the treatment of radioresistant tumors: the ETOILE trial

Jacques Balosso1*, Olivia Febvey-Combes2, Annie Jlung3, Hélène Lozano2, Abdoulkader Soumai Alloh3, Catherine Cornu4,5, Magali Herve2, Zohra Akkal3, Michel Lièvre3, Valérie Plattner3, Francesca Valvo6, Cristina Bono6, Maria Rosaria Fiore5, Viviana Vitolo6, Barbara Vischioni6, Stéphanie Patin7, Hubert Allemand8, François Gueyffier2,4, Jennifer Margier2, Pascale Guerre2,9, Sylvie Chabaud10, Roberto Orecchia6,11 and Pascal Pommier12

Abstract

Background: Some cancers such as sarcomas (bone and soft tissue sarcomas) and adenoid cystic carcinomas are considered as radioresistant to low linear energy transfer radiation (including photons and protons) and may therefore benefit from a carbon ion therapy. Despite encouraging results obtained in phase I/II trials compared to historical data with photons, the spread of carbon ions has been limited mainly because of the absence of randomized medical data. The French health authorities stressed the importance of having randomized data for carbon ion therapy.

Methods: The ETOILE study is a multicenter prospective randomized phase III trial comparing carbon ion therapy to either advanced photon or proton radiotherapy for inoperable or macroscopically incompletely resected (R2) radioresistant cancers including sarcomas and adenoid cystic carcinomas.

In the experimental arm, carbon ion therapy will be performed at the National Center for Oncological Hadrontherapy (CNAO) in Pavia, Italy. In the control arm, photon or proton radiotherapy will be carried out in referent centers in France.

The primary endpoint is progression-free survival (PFS). Secondary endpoints are overall survival and local control, toxicity profile, and quality of life. In addition, a prospective health-economic study and a radiobiological analysis will be conducted.
To demonstrate an absolute improvement in the 5-year PFS rate of 20% in favor of carbon ion therapy, 250 patients have to be included in the study.

**Discussion:** So far, no clinical study of phase III has demonstrated the superiority of carbon ion therapy compared to conventional radiotherapy, including proton therapy, for the treatment of radioresistant tumors.

**Trial registration:** ClinicalTrials.gov identifier: NCT02838602. Date of registration: July 20, 2016. The posted information will be updated as needed to reflect protocol amendments and study progress.

**Keywords:** Radiotherapy, Carbon ion therapy, Proton therapy, Photon therapy, Radioresistant tumors

**Background**

Radiotherapy is improving rapidly and is being enhanced by innovative high-technology equipment using hadrontherapy by proton and carbon ion beams to destroy tumours [1, 2]. Compared to photons (X-rays), a beam of heavy charged particles (protons and carbon ions) enables significantly higher ballistic accuracy with the expected therapeutic benefit of an improvement of quality of life and chances of recovery [3].

Inherently mediocre ballistics selectivity of photons can be compensated by the use of a large number of beams (multiplication of entrance portals) and by modulation of the intensity of the beam enabling the dose to be accurately conformed to the target volume, with the main consequence of irradiating a much larger volume of healthy tissue to medium and low doses. This technique is used for innovative methods of photon radiation therapy: intensity-modulated radiation therapy (IMRT) using either advanced linear accelerators or specific tomotherapy devices and, for small volume tumors, stereotactic radiotherapy using either a conventional linear accelerator specially equipped or a dedicated mini-accelerator mounted on a robotic arm (the Cyberknife®).

Carbon ions also have a much higher biological efficiency (cell destruction) at the Bragg peak (and not in the entrance channel) at the same physical dose than so-called low linear energy transfer (LET) radiation, such as photons and protons [4, 5]. This relative biological effectiveness (RBE) is variable depending on the tissues passed through and is markedly higher for radioresistant cancers [6]. This intrinsic radiological property is the main argument for the use of carbon ions compared to protons.

Carbon ion radiotherapy has shown promising results for a variety of malignancies in prospective phase I/II or phase II studies [4, 7]. In particular, the medical benefit of carbon ions is expected to be major for non-operable (or incompletely resected) localized cancers that are radioresistant to low LET (photons and protons) and located near radiosensitive organs at risk. However, high level evidence from phase III studies demonstrating the benefit of carbon ions is not available [5, 8].

Certain types of cancers are known for their intrinsic radioresistance (melanomas, some sarcomas, adenoid cystic carcinomas) and are thus the main indications of carbon ions. Other types of cancers that are more frequent (e.g., squamous cell carcinomas, adenocarcinomas) may have extremely variable radiosensitivity, linked in particular to the existence of tumor hypoxia, but also to intrinsic biological characteristics that are still poorly understood and difficult to prospectively identify.

In the present study, two groups of indications known for their intrinsic radioresistance and for which the medical data obtained in the pioneering centers for carbon ion therapy are the most documented will be considered: sarcomas [9, 10] and adenoid cystic carcinomas of the head and neck [11–14]. Spinal and sacral chordomas and chondrosarcomas are duly included, but similar tumours of the base of the skull are currently the subject of randomized phase III studies comparing protons and carbon ions, and are thus excluded from the indications of the present study [15, 16].

We set up a multicenter randomized phase III study aimed at evaluating the clinical benefit of hadrontherapy based on carbon ions compared to the best modalities of photon radiation therapy or protons in these radioresistant tumors.

**Methods and design**

**Study design**

The ETOILE trial is a multicenter open-label randomized parallel-group superiority trial comparing carbon ion therapy with standard radiotherapy, including a treatment by photons or protons. Patients will be enrolled in French reference centers for cancer treatment. Patients fulfilling the eligibility criteria will be randomized into two arms using a 1:1 ratio (experimental arm: carbon ion therapy; control arm: photon or proton therapy). Follow-up takes place 2 months and 6 months after the end of radiotherapy, then every 6 months during 5 years.

**Study objectives and endpoints**

The primary outcome is the progression-free survival (PFS) defined as the time from randomization to the first relapse or death, whatever the cause, or to the latest news date. Progression is defined according to RECIST v1.1 criteria [17] based on standard medical imaging (CT or
MRI), and confirmed 6 months later. An independent committee unaware of the treatment group will validate all progressions.

Secondary outcomes include: the tolerance profile assessed using CTCAE-V4.02 grades; survival without locoregional progression; survival without metastases; overall survival; quality of life using the EQ-5D-3L. Associated health-economic and radiobiological studies are also planned.

Patient selection

Inclusion/randomization criteria

Patients eligible for inclusion in this study have to meet all of the following criteria:

- age \( \geq 18 \) years
- unresectable or inoperable cancer or a cancer with a macroscopically incomplete resection (R2)
- radioresistant cancers including: adenoid cystic carcinomas of the head and neck (excluding laryngeal and tracheal sites), soft tissue sarcomas, rhabdomyosarcoma of pleomorphic type only, retroperitoneal sarcomas providing technical feasibility, osteosarcomas of any localization and whatever the grade (Ewing's sarcomas excluded), chondrosarcoma (excluding skull base) of WHO grade \( \geq 2 \), chordomas of the axial skeleton and the pelvis (base of the skull excluded), and angiosarcomas (scalp angiosarcoma excluded).
- absence of epidermal invasion (a hypodermic invasion is accepted with cutaneous adherence but no permeation of the epidermis);
- largest dimension of the macroscopic volume (Gross Tumor Volume, GTV) < 20 cm;
- Performance Status ECOG \( \leq 2 \) or Karnofsky Index \( \geq 60 \);
- no severe comorbidities and life expectancy over 10 years;
- patient physically and mentally able to accept and receive cares far from their home;
- no ongoing pregnancy or risk of pregnancy for women of childbearing age;
- patient affiliated with a social security insurance;
- written informed consent to participate in the study.

Additional criteria are requested for randomization:

- validation of an indication for radiotherapy by a specialized local multidisciplinary tumor board (MTB) and, in the context of the indications of this study, validation of the indication and the feasibility for carbon ion therapy by the medical team of the National Center for Oncological Hadrontherapy (CNAO) in Pavia, Italy;
- possibility of offering carbon ion therapy within 2 months.

Non-inclusion/non-randomization criteria

Patients eligible for this study must not meet any of the following criteria:

- macroscopically or microscopically complete surgical excision (R0 or R1);
- a history of radiotherapy on the site and region to be treated;
- metastatic disease;
- disease not relevant for a curative approach (e.g. a very advanced disease with extensive regional invasion or with accelerated progression resistant to all medical treatments, especially sarcomas);
- contra-indication to the realization of a radiotherapy (by photons, protons or carbon ions) for medical or technical reasons;
- pre-scheduled surgery or chemotherapy after radiotherapy;
- a history or concomitant presence of another cancer; with the exception of an in situ cervical cancer or curatively treated basal cell cutaneous carcinoma or any other curatively treated cancer without signs of a relapse for at least 5 years;
- simultaneous participation in another prospective trial;
- patient unable to be followed-up for 5 years.

Randomization

Randomization will be done using an Interactive Web Response Systems (IWRS). Stratification parameters include the center and the type of cancer (adenoid cystic carcinoma versus sarcoma and chordoma). As the trial design is open-label, no blinding of treatment assignment is possible.

Reference committee

An Independent Data Safety Monitoring Board (IDSMB) is established to ensure the protection of patients, to ensure that the study is conducted in an ethical manner, to systematically reassess the benefit-risk balance of the trial and to ensure the independent review of the scientific results under study. The IDSMB will be composed of independent experts in the field of radiation oncology and methodology of clinical trials.
Radiation therapy

Experimental arm: carbon ion therapy
In the carbon ion arm, patients will not receive conventional radiotherapy. For all patients randomized in this treatment arm, carbon therapy will be delivered at the CNAO in Pavia, Italy. The total duration of treatment will be 4 weeks (16 sessions, 4 sessions per week). Patients will receive support from the study team and the local team for their transportation and housing.

Control arm: standard photon or proton therapy
Patients will be able to receive two different types of radiotherapy in the control arm (photon or proton therapy). Standard treatment will be delivered in French regional centers for cancer treatment and university hospital centers, some private centers, and proton therapy centers.

Radiotherapy with intensity modulation (IMRT) will be delivered using most advanced procedures in the center recruiting the patients, after one or more preparation sessions (scanner, simulation and implementation under machine, verification by quality control imaging). The IMRT solution will be left to the investigator’s choice (standard IMRT, dynamic arctherapy, tomotherapy) according to local technical availability and the clinical situation. 3D conformal radiation therapy without intensity modulation will also be an option if it allows dosimetric results comparable to those of IMRT on the basis of the resulting dose-volume-histograms (DVH). All recommended technical modalities in terms of contention, repositioning capacity and quality control for image-guided radiation therapy (IGRT) will be implemented. Planned and performed treatment data will be recorded according to the current recommendations of the International Commission on Radiation Units and Measurements (ICRU).

Deep proton therapy will be performed only for some patients based on quantitative criteria for probable differences in normal tissue complication probability (NTCP) calculated by comparing a photon treatment plan with a proton treatment plan. The indication of proton therapy may result from the observation of an excessive toxic risk with photon therapy. Proton therapy can be exclusive or complementary to a photon therapy treatment when a low-risk volume is defined and substantially greater than the high-risk volume. In cases of photon-proton association, the proton part will be carried out first in order to give the maximum of possibilities to adapt to the anatomical constraints without being disturbed by previously received doses. The use of proton therapy will be decided using an objective approach described in Fig. 1.

This strategy will offer the opportunity to scientifically evaluate the feasibility and relevance of this approach based on NTCP models [18].

---

![Diagram](image.png)

Fig. 1  Choice between photon and proton therapy in the control arm. ∆NTCP, Difference in normal tissue complication probability; LOAR, Dose limits of organs at risk; OAR, Organs at risk; RD, Recommended doses

---

Balosso et al. BMC Cancer (2022) 22:575
Dose prescription
In the experimental arm, the carbon ion therapy will be delivered according to the methods of the National Institute of Radiological Sciences (NIRS), Japan, and the Heidelberg Ion-Beam Therapy Center (HIT), Germany, adapted by the CNAO. As an indication, doses of carbon ion therapy to deliver are given in Table 1.

For patients included in the standard arm (photon or proton therapy), minimum recommended doses are given in Table 2.

These dose recommendations are given for information purposes and are likely to change over time.

General organization
A central platform from the Heidelberg Institute for Radiation Oncology (HIRO), the so-called HIRO-ULICE platform, will be used for storage and exchange of data such as anonymized medical imaging and patient medical records. This platform will allow the review of patient documents by proton centers for patients in the standard group requiring proton therapy, the confirmation by CNAO that carbon therapy is feasible, and a quality control by the study team. Figure 2 presents the workflow.

The Ennov Clinical trial software (version 8.2.50) will be used for randomization, clinical data collection, and central data management.

Sample size calculation
The study is calibrated to detect a treatment effect hazard ratio (HR) of 0.515 under the proportional hazards assumption, translating in an absolute improvement of the 5-year PFS rate of 20% in favor of the experimental arm (70% in the experimental arm vs 50% in the control arm).

A total of 92 events [East Software- Copyright@Cytel inc. 1994] notified in the study would have 90% power to show statistically significant PFS at a 2-sided alpha. Considering initial recruitment duration of 24 months and a 5-year follow-up for the last included patient, 108 patients per arm would be randomized in the study. To optimize the study and consider the possibility of withdrawal of consent and patients lost to follow-up, the recruitment objective was set at 250 patients.

### Table 1

| Diseases                  | Methods       | Doses (Gy (IsoE)) |
|---------------------------|---------------|-------------------|
| Adenoid cystic carcinomas | CNAO          | 60.8 to 64.0      |
| Sarcomas                  | CNAO          | 70.4 to 73.6      |
| Chordomas                 | CNAO          | 70.4 to 73.6      |

*a adapted from the experience of NIRS, National Institute of Radiological Sciences (Japan) and HIT, Heidelberg Ion-Beam Therapy Center (Germany)*

*b All treatments are delivered in 16 fractions, 4 fractions per week*  
CNAO, National Center for Oncological Hadrontherapy; IsoE, Isoeffective dose to $^{60}$Co or Rx doses delivered with 2 Gy per fraction

### Table 2

| Diseases                  | Methods                        | Doses (Gy (EQD2)) |
|---------------------------|--------------------------------|-------------------|
| Adenoid cystic carcinomas | GTV integrated boost           | 66                |
|                           | CTV high-risk                  | 60 in 30 fractions|
|                           | CTV low-risk                   | 54                |
| Osteosarcomas             | conventional fractionation     | 64 to 70          |
| Chondrosarcomas           | conventional fractionation     | 64 to 70          |
| Chordomas                 | MGH Boston (protons)           | 78                |
|                           | IMRT (photons)                 | 71                |
| Soft tissue sarcomas      | conventional fractionation     | 64 to 70          |

CTV Clinical target volume, EQD2 Equivalent dose with 2 Gy per fraction, GTV Gross tumor volume, IMRT Intensity-modulated radiation therapy, MGH Massachusetts General Hospital
Statistical analysis

Primary endpoint
The primary endpoint will be analyzed on the intention-to-treat (ITT) population comprising all randomized patients in the arm where they were randomized. A per-protocol analysis will also be performed in patients without major deviation from the protocol. The evaluable population for treatment tolerance will be all patients who received at least one session of radiotherapy of any kind. PFS will be calculated from the date of randomization to the date of first evidence of a documented relapse, or until the date of death regardless of cause, or until the date of last news (data from patients who did not present the event at the time of the analysis will be censored). It will be estimated in each arm by the Kaplan-Meier method and compared between the two treatment arms by a Log-Rank test.

Secondary endpoints
The overall survival analysis will be performed in the ITT population using the same methods. Tolerance assessments will be conducted throughout treatment and will continue until completion of follow-up using CTCAE-V4.02 criteria. Two periods will be distinguished, events appearing during or within 2 months of the treatment period and late toxicities appearing within 5 years after the end of treatment and which will be considered attributable to radiotherapy. The rate of patients with at least one adverse event will be compared between the two treatment arms.

Quality of life will be evaluated at baseline, at 6 months and then at 1 year and annually until the fifth year of follow-up after treatment using the EQ-5D questionnaire. The quality of life analysis will be carried out on the ITT population. The level of quality of

Fig. 2 Workflow diagram. ACC, Adenoid cystic carcinomas; CNAO, National Center for Oncological Hadrontherapy; MTB, Multidisciplinary tumor board.
life at inclusion and its evolution during the monitoring period will be compared between the treatment arms. The 10% difference between initial assessment and subsequent assessments of the overall quality of life score will be considered clinically relevant as defined by Osoba et al. [19, 20].

**Interim analysis**

An interim analysis is planned for effectiveness or futility. This analysis will be carried out when approximately 50% (46 events) of the final number of PFS events has been reached. The significance level at this interim analysis to establish the superiority or futility of experimental treatment over control with regard to PFS will be determined based on the observed number of events, using the O’Brien & Fleming boundaries as implemented by the Lan-DeMets alpha spending method (Lan and DeMets 1983) in order to control the overall Type I error rate.

Using planned enrollment rate, this analysis should be performed 42 months after first included patient. For example, if the number of events at the time of interim efficacy analysis is exactly 46, the bounds to use during this analysis according to Lan Demets rules will be $p = 0.0031$ and $p = 0.8443$ respectively to reject H0 and H1.

**Health economic analysis**

The main objective is to evaluate the efficiency of a treatment with carbon ions compared to the standard treatments used in the specific indications of the clinical study. We will performed both Cost-Effectiveness Analysis (CEA) and Cost-Utility Analysis (CUA) at 5 years from French public health care system perspective. The endpoints are the incremental cost-effectiveness ratios (ICERs). They are defined by the difference in cost between the two interventions, divided by the difference in effect. The effects will be measured by the overall survival for the CEA and by the quality-adjusted life years (QALY) for the CUA. Utility will be measured with the EQ-5D-3L questionnaire.

Additionally, in this study carbon ion therapy is carried out abroad and invoiced to the French National Health Insurance Fund (CNAM). Under the hypothesis of a newly implanted hadrontherapy center in France, we will have to estimate the cost of this future act of treatment (and its associated preparation act) for the hospital. We will rely on data from the literature (cost studies carried out in France and abroad) and from the Italian and German experts (concerning the average time spent by the various categories of staff for the various stages of processing and its preparation).

**Radiobiological analysis**

Initial biopsy samples will be analyzed by large-scale genomic processes to identify genetic tumor profiles correlated with the clinical outcomes. This part of the study will be carried out during the course of the trial.

**Discussion**

When indicated, conventional radiotherapy is currently the reference in the treatment of bone and soft tissue sarcomas as well as adenoid cystic carcinomas. High-LET beams such as carbon ions theoretically offer biologic advantages compared to conventional radiotherapy in these indications. The ETOILE study is thus designed as a prospective multicenter randomized phase III trial evaluating the superiority of carbon ion therapy over conventional methods including photons and protons, and will be carried out in France and Italy. Several factors have limited the spread of carbon ion therapy. First of all, the absence of randomized medical data that would conclusively demonstrate the therapeutic gain provided by carbon ion therapy, linked to a very limited treatment capacity but also to the difficulty in establishing a reference comparator treatment for these rare indications [21].

The opening of the HIT in Germany in 2009 marked a crucial turning point in the establishment of randomized protocols comparing protons and carbon ions for different locations [15, 16, 22–24]. More recently, other randomized trials are planned to be conducted in carbon ion therapy centers worldwide [8, 25–27]. Carbon ion therapy has already been applied to more than 40,000 patients worldwide, including about 50 patients in France. So far, there is no available evidence from randomized phase III studies of the efficacy of carbon ion therapy on cancer outcomes [5, 8]. Moreover, to the best of our knowledge, all advanced phase III trials are carried out as monocentric trials restricting generalizability.

The primary aim of the ETOILE study is to demonstrate whether the biological advantages of carbon ion therapy can be translated as a clinical advantage, and to evaluate the predictive value of molecular markers, for a better orientation of the patients requiring a treatment by carbon ion therapy.

**Status of the trial**

The ETOILE study started in December 2017 and patient recruitment is ongoing at March 23, 2022.

**Abbreviations**

CNAO: National Center for Oncological Hadrontherapy; CTV: Clinical target volume; GTV: Gross Tumor Volume; HIRO: Heidelberg Institute for Radiation
Oncology; HIT: Heidelberg Ion-Beam Therapy Center; IMRT: Intensity-modulated radiation therapy; LET: Linear energy transfer; MTB: Multidisciplinary tumor board; NIRS: National Institute of Radiological Sciences; NTCP: Normal tissue complication probability; PFS: Progression-free survival.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12888-022-09564-7.

Additional file 1. ETOILE trial – List of participating centers. Full names of all participating centers.

Acknowledgements

We want to thank the ULICE project for the so-called HIRO-ULICE platform, which is a specific service provided by the NEXUS/CHILI GmbH, Dossenheim, Germany, near Heidelberg, initially developed for hadrontherapy clinical research purposes and having been co-funded in the frame of the European Commission FP7 INFRASTRUCTURE – 2008 – 1 – 228436 agreement: ULICE project.

Authors’ contributions

Study concept and design: JB, ML, SP, HA, SC, RO and PP; writing committee: JB, OF–C, ML, SP, SC, and PP; administration and legal issues: AI, CC, ZA, VP, CB, HA and FG; data management: OF–C, CC, MH, HL, FG, JM and PG; CNAO participation: FV, CB, MRF, VV, BV and RO; methodology and statistics: ML and SC; running of the study, assistance to the investigators, monitoring: JB, HL, ASA, FV, CB, FG and PP. All authors contributed to and approved the final manuscript.

Funding

The trial is funded by the Programme Hospitalier de Recherche Clinique en cancérologie (PHRC-K, 2011) from the French Ministry of Health, and the study protocol has undergone external peer review during the funding process. The French National Health Insurance Fund (Caisse nationale de l'Assurance Maladie; CNAM) pays for the experimental treatment. The French League against cancer (Ligue Nationale contre le Cancer) agrees to support patients when needed. The funders will not be involved in data collection, analysis, and interpretation of data.

Availability of data and materials

Data generated or analyzed during the study will be available from the corresponding author on reasonable request. Results will be communicated via publications in peer-reviewed journals and presentations at international conferences.

Declarations

Ethics approval and consent to participate

The ETOILE study was approved by the French Ethics Committee (Comité de Protection des Personnes Sud Est N, Lyon, France), and authorized by the French and Italian competent authorities. It will be conducted according to the Helsinki declaration, and in the respect of the Good Clinical Practices. Patients will be informed in a comprehensive and fair manner, in understandable terms, and will give their written consent. A list of all participating centers is added as Supplementary file (see Additional file 1).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Centre François Baclesse, Service de radiothérapie, BP 45026, F-14076 Caen, Cedex 5, France. 2Hospices Civils de Lyon, Pôle de Santé Publique, Lyon, France. 3Hospices Civils de Lyon, Direction de la Recherche en Santé, Lyon, France. 4LUMS558, Université Claude Bernard Lyon 1, Lyon, France. 5INSERM, CIC1407, Hospices Civils de Lyon, Bron, France. 6Centro Nazionale di Adroterapia Oncologica, Pavia, Italy. 7Groupement Coopération Sanitaire Centre Etoile, Lyon, France. 8Caisse Nationale d’Assurance Maladie des Travailleurs Salariés, Paris, France. 9Université de Lyon, Université Claude Bernard Lyon 1, PPS, UFR129, Lyon, France. 10Centre Léon Bérard, Direction de la Recherche Clinique et de l’Innovation, Lyon, France. 11European Institute of Oncology IRCCS, Milan, Italy. 12Centre Léon Bérard, Service de Radiothérapie, Lyon, France.

Received: 29 March 2022 Accepted: 17 April 2022

Published online: 23 May 2022

References

1. Suit H, Goldberg S, Niemierko A, Trofimov A, Adams J, Paganetti H, et al. Proton beams to replace photon beams in radical dose treatments. Acta Oncol. 2003;42(8):800–8.
2. Suit H. The gray lecture 2001: coming technical advances in radiation oncology. Int J Radiat Oncol Biol Phys. 2002;53(4):799–809.
3. Orecchia R, Kengli M, Jereczek-Fossa BA, Franzetti S, Gerard JP. Clinical and research validity of hadrontherapy with ion beams. Crit Rev Oncol Hematol. 2004;51(2):81–90.
4. Tsuji H, Kamada T. A review of update clinical results of carbon ion radiotherapy. Jpn J Clin Oncol. 2012;42(8):670–84.
5. Rackwitz T, Debus J. Clinical applications of proton and carbon ion therapy. Semin Oncol. 2019;46(3):226–32.
6. Ando K, Kase Y. Biological characteristics of carbon-ion therapy. Int J Radiat Biol. 2009;85(9):715–28.
7. Tsuji H, Mizoe JE, Kamada T, Baba M, Kato S, Kato H, et al. Overview of clinical experiences on carbon ion radiotherapy at NIRS. Radiother Oncol. 2004;73(Suppl 2):S41–9.
8. Lazar AA, Schulte R, Faddegon B, Blakely EA, Roach M 3rd. Clinical trials involving carbon-ion radiation therapy and the path forward. Cancer. 2018;124(23):4467–76.
9. Weber DC, Rutz HP, Pedroni ES, Bolli A, Timmermann B, Verwey J, et al. Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: the Paul Scherer Institut experience. Int J Radiat Oncol Biol Phys. 2005;63(2):401–9.
10. Kamada T, Tsuji H, Tsuji H, Yanagi T, Mizoe JE, Miyamoto T, et al. Efficacy and safety of carbon ion radiotherapy in bone and soft tissue sarcomas. J Clin Oncol. 2002;20(22):4466–71.
11. Schulz-Ertner D, Nikoghosyan A, Didinger B, Munter M, Jakel O, Karger CP, et al. Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques. Cancer. 2005;104(2):338–44.
12. Munter MW, Schulz-Ertner D, Hof H, Nikoghosyan A, Jensen A, Nill S, et al. Inverse planned stereotactic intensity modulated radiotherapy (IMRT) in the treatment of incompletely and completely resected adenoid cystic carcinomas of the head and neck: initial clinical results and toxicity of treatment. Radiat Oncol. 2006;1:17.
13. Mizoe JE, Tsuji H, Kamada T, Matsuoka Y, Tsuji H, Osaka Y, et al. Dose escalation study of carbon ion radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004;60(2):558–64.
14. Pommier R, Liebsch NJ, Deschler DG, McIntyre JF, Barker FG 2nd, et al. Proton beam radiation therapy for skull base adenoid cystic carcinoma. Arch Otolarngol Head Neck Surg. 2006;132(11):1242–9.
15. Nikoghosyan AV, Karsanagiotou-Schenkel I, Munter MW, Jensen AD, Combs SE, Debus J. Randomised trial of proton vs. carbon ion radiation therapy in patients with chordoma of the skull base, clinical phase III study HIT-1-study. BMC Cancer. 2010;10:607.
16. Nikoghosyan AV, Rauch G, Munter MW, Jensen AD, Combs SE, Kieser M, et al. Randomised trial of proton vs. carbon ion radiation therapy in patients with low and intermediate grade chondrosarcoma of the skull base, clinical phase III study. BMC Cancer. 2010;10:606.
17. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
18. Chakib A, Thariat J, Thureau S, Tessonnier T, Kummerer E, Fontbonne C, et al. Construction of radiobiological models as TCP (tumor control probability) and NTCP (normal tissue complication probability): from dose to clinical effects prediction. Cancer Radiother. 2020;24(3):247–57.
19. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139–44.

20. Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J. Quality of life committee of the NC: analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of the National Cancer Institute of Canada clinical trials group. Eur J Cancer. 2005;41(2):280–7.

21. Goitein M. Trials and tribulations in charged particle radiotherapy. Radiother Oncol. 2010;95(1):23–31.

22. Combs SE, Burkholder L, Rieken S, Habermehl D, Jakel O, et al. Randomised phase II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: the CINDERELLA trial. BMC Cancer. 2010;10:533.

23. Combs SE, Kieser M, Rieken S, Habermehl D, Jakel O, Haberer T, et al. Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial. BMC Cancer. 2010;10:478.

24. Combs SE, Jakel O, Haberer T, Debys J. Particle therapy at the Heidelberg ion therapy center (HIT) - integrated research-driven university-hospital-based radiation oncology service in Heidelberg, Germany. Radiother Oncol. 2010;95(1):41–4.

25. Kong L, Gao J, Hu J, Lu R, Yang J, Qiu X, et al. Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase II clinical trial. Cancer Commun (Lond). 2019;39(1):S.

26. Lang K, Adeberg S, Harrabi S, Held T, Kieser M, Debus J, et al. Adenoid cystic carcinoma and carbon ion only irradiation (ACCO): study protocol for a prospective, open, randomized, two-armed, phase II study. BMC Cancer. 2021;21(1):812.

27. Malouff TD, Mahajan A, Krishnan S, Beltran C, Seneviratne DS, Trifiletti DM. Carbon ion therapy: a modern review of an emerging technology. Front Oncol. 2020;10:82.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.